John G Hanly1, Aidan G O'Keeffe2, Li Su3, Murray B Urowitz4, Juanita Romero-Diaz5, Caroline Gordon6, Sang-Cheol Bae7, Sasha Bernatsky8, Ann E Clarke9, Daniel J Wallace10, Joan T Merrill11, David A Isenberg12, Anisur Rahman12, Ellen M Ginzler13, Paul Fortin14, Dafna D Gladman4, Jorge Sanchez-Guerrero4, Michelle Petri15, Ian N Bruce16, Mary Anne Dooley17, Rosalind Ramsey-Goldman18, Cynthia Aranow19, Graciela S Alarcón20, Barri J Fessler20, Kristjan Steinsson21, Ola Nived22, Gunnar K Sturfelt22, Susan Manzi23, Munther A Khamashta24, Ronald F van Vollenhoven25, Asad A Zoma26, Manuel Ramos-Casals27, Guillermo Ruiz-Irastorza28, S Sam Lim29, Thomas Stoll30, Murat Inanc31, Kenneth C Kalunian32, Diane L Kamen33, Peter Maddison34, Christine A Peschken35, Soren Jacobsen36, Anca Askanase37, Chris Theriault38, Kara Thompson38, Vernon Farewell3. 1. Division of Rheumatology, Department of Medicine and Department of Pathology, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, Nova Scotia, Canada, john.hanly@cdha.nshealth.ca. 2. Department of Statistical Science, University College London, London. 3. MRC Biostatistics Unit, Institute of Public Health, University Forvie Site, Cambridge, UK. 4. Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada. 5. Instituto Nacional de Ciencias Medicas y Nutrición, Mexico City, Mexico. 6. Rheumatology Research Group, School of Immunity and Infection, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK. 7. Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea. 8. Divisions of Rheumatology and Clinical Epidemiology, McGill University Health Centre. 9. Division of Rheumatology, University of Calgary, Alberta, Canada. 10. Cedars-Sinai/David Geffen School of Medicine at UCLA, Los Angeles, CA. 11. Department of Clinical Pharmacology, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA. 12. Centre for Rheumatology, Department of Medicine, University College London, UK. 13. Department of Medicine, SUNY Downstate Medical Center, Brooklyn, NY, USA. 14. Division of Rheumatology, Centre Hospitalier Universitaire de Québec et Université Laval, Quebec City, Canada. 15. Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 16. Arthritis Research UK Epidemiology Unit, Institute of Inflammation and Repair, Manchester Academic Health Sciences Centre, The University of Manchester, Manchester, UK, NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK. 17. Thurston Arthritis Research Center, University of North Carolina, Chapel Hill, NC. 18. Northwestern University and Feinberg School of Medicine, Chicago, IL. 19. Feinstein Institute for Medical Research, Manhasset, NY. 20. Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA. 21. Center for Rheumatology Research, Landspitali University Hospital, Reykjavik, Iceland. 22. Department of Rheumatology, University Hospital Lund, Lund, Sweden. 23. Division of Rheumatology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. 24. Lupus Research Unit, The Rayne Institute, St Thomas' Hospital, King's College London School of Medicine, London, UK. 25. Unit for Clinical Therapy Research, Karolinska Institute, Stockholm, Sweden. 26. Lanarkshire Centre for Rheumatology, Hairmyres Hospital, East Kilbride, Scotland, UK. 27. Josep Font Autoimmune Diseases Laboratory, IDIBAPS, Department of Autoimmune Diseases, Hospital Clínic, Barcelona, Spain. 28. Autoimmune Diseases Research Unit, Department of Internal Medicine, BioCruces Health Research Institute, Hospital Universitario Cruces, University of the Basque Country, Barakaldo, Spain. 29. Emory University School of Medicine, Division of Rheumatology, Atlanta, Georgia, USA. 30. Kantonsspital Geissbergstr, Schaffhausen, Switzerland. 31. Division of Rheumatology, Department of Internal Medicine, Istanbul Medical Faculty, Istanbul University, Istanbul, Turkey. 32. UCSD School of Medicine, La Jolla, CA. 33. Medical University of South Carolina, Charleston, SC, USA. 34. Ysbyty Gwynedd Bangor, Gwynedd, North Wales, UK. 35. University of Manitoba, Winnipeg, Manitoba, Canada. 36. Department of Rheumatology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. 37. Hospital for Joint Diseases, NYU, Seligman Centre for Advanced Therapeutics, New York, NY, USA and. 38. Department of Medicine, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, Nova Scotia, Canada.
Abstract
OBJECTIVE: To determine nephritis outcomes in a prospective multi-ethnic/racial SLE inception cohort. METHODS: Patients in the Systemic Lupus International Collaborating Clinics inception cohort (≤15 months of SLE diagnosis) were assessed annually for estimated glomerular filtration rate (eGFR), proteinuria and end-stage renal disease (ESRD). Health-related quality of life was measured by the Short Form (36 questions) health survey questionnaire (SF-36) subscales, mental and physical component summary scores. RESULTS: There were 1827 patients, 89% females, mean (s.d.) age 35.1 (13.3) years. The mean (s.d.) SLE duration at enrolment was 0.5 (0.3) years and follow-up 4.6 (3.4) years. LN occurred in 700 (38.3%) patients: 566/700 (80.9%) at enrolment and 134/700 (19.1%) during follow-up. Patients with nephritis were younger, more frequently men and of African, Asian and Hispanic race/ethnicity. The estimated overall 10-year incidence of ESRD was 4.3% (95% CI: 2.8%, 5.8%), and with nephritis was 10.1% (95% CI: 6.6%, 13.6%). Patients with nephritis had a higher risk of death (HR = 2.98, 95% CI: 1.48, 5.99; P = 0.002) and those with eGFR <30 ml/min at diagnosis had lower SF-36 physical component summary scores (P < 0.01) and lower Physical function, Physical role and Bodily pain scores. Over time, patients with abnormal eGFR and proteinuria had lower SF-36 mental component summary (P ≤ 0.02) scores compared to patients with normal values. CONCLUSION: LN occurred in 38.3% of SLE patients, frequently as the initial presentation, in a large multi-ethnic inception cohort. Despite current standard of care, nephritis was associated with ESRD and death, and renal insufficiency was linked to lower health-related quality of life. Further advances are required for the optimal treatment of LN.
OBJECTIVE: To determine nephritis outcomes in a prospective multi-ethnic/racial SLE inception cohort. METHODS: Patients in the Systemic Lupus International Collaborating Clinics inception cohort (≤15 months of SLE diagnosis) were assessed annually for estimated glomerular filtration rate (eGFR), proteinuria and end-stage renal disease (ESRD). Health-related quality of life was measured by the Short Form (36 questions) health survey questionnaire (SF-36) subscales, mental and physical component summary scores. RESULTS: There were 1827 patients, 89% females, mean (s.d.) age 35.1 (13.3) years. The mean (s.d.) SLE duration at enrolment was 0.5 (0.3) years and follow-up 4.6 (3.4) years. LN occurred in 700 (38.3%) patients: 566/700 (80.9%) at enrolment and 134/700 (19.1%) during follow-up. Patients with nephritis were younger, more frequently men and of African, Asian and Hispanic race/ethnicity. The estimated overall 10-year incidence of ESRD was 4.3% (95% CI: 2.8%, 5.8%), and with nephritis was 10.1% (95% CI: 6.6%, 13.6%). Patients with nephritis had a higher risk of death (HR = 2.98, 95% CI: 1.48, 5.99; P = 0.002) and those with eGFR <30 ml/min at diagnosis had lower SF-36 physical component summary scores (P < 0.01) and lower Physical function, Physical role and Bodily pain scores. Over time, patients with abnormal eGFR and proteinuria had lower SF-36 mental component summary (P ≤ 0.02) scores compared to patients with normal values. CONCLUSION: LN occurred in 38.3% of SLE patients, frequently as the initial presentation, in a large multi-ethnic inception cohort. Despite current standard of care, nephritis was associated with ESRD and death, and renal insufficiency was linked to lower health-related quality of life. Further advances are required for the optimal treatment of LN.
Authors: S Jacobsen; J Petersen; S Ullman; P Junker; A Voss; J M Rasmussen; U Tarp; L H Poulsen; G van Overeem Hansen; B Skaarup; T M Hansen; J Pødenphant; P Halberg Journal: Clin Rheumatol Date: 1998 Impact factor: 2.980
Authors: Emily C Somers; Wendy Marder; Patricia Cagnoli; Emily E Lewis; Peter DeGuire; Caroline Gordon; Charles G Helmick; Lu Wang; Jeffrey J Wing; J Patricia Dhar; James Leisen; Diane Shaltis; W Joseph McCune Journal: Arthritis Rheumatol Date: 2014-02 Impact factor: 10.995
Authors: S Sam Lim; A Rana Bayakly; Charles G Helmick; Caroline Gordon; Kirk A Easley; Cristina Drenkard Journal: Arthritis Rheumatol Date: 2014-02 Impact factor: 10.995
Authors: G S Cooper; C G Parks; E L Treadwell; E W St Clair; G S Gilkeson; P L Cohen; R A S Roubey; M A Dooley Journal: Lupus Date: 2002 Impact factor: 2.911
Authors: Mary Anne Dooley; David Jayne; Ellen M Ginzler; David Isenberg; Nancy J Olsen; David Wofsy; Frank Eitner; Gerald B Appel; Gabriel Contreras; Laura Lisk; Neil Solomons Journal: N Engl J Med Date: 2011-11-17 Impact factor: 91.245
Authors: Cecile Grootscholten; Frank J Snoek; Marc Bijl; Hans C van Houwelingen; Ronald H W M Derksen; Jo H M Berden Journal: J Rheumatol Date: 2007-07-15 Impact factor: 4.666
Authors: Ricard Cervera; Munther A Khamashta; Josep Font; Gian Domenico Sebastiani; Antonio Gil; Paz Lavilla; Juan Carlos Mejía; A Olcay Aydintug; Hanna Chwalinska-Sadowska; Enrique de Ramón; Antonio Fernández-Nebro; Mauro Galeazzi; Merete Valen; Alessandro Mathieu; Frédéric Houssiau; Natividad Caro; Paula Alba; Manuel Ramos-Casals; Miguel Ingelmo; Graham R V Hughes Journal: Medicine (Baltimore) Date: 2003-09 Impact factor: 1.889
Authors: Jill P Buyon; Mimi Y Kim; Marta M Guerra; Sifan Lu; Emily Reeves; Michelle Petri; Carl A Laskin; Michael D Lockshin; Lisa R Sammaritano; D Ware Branch; T Flint Porter; Allen Sawitzke; Joan T Merrill; Mary D Stephenson; Elisabeth Cohn; Jane E Salmon Journal: Clin J Am Soc Nephrol Date: 2017-04-11 Impact factor: 8.237
Authors: Juan M Mejia-Vilet; Samir V Parikh; Huijuan Song; Paolo Fadda; John P Shapiro; Isabelle Ayoub; Lianbo Yu; Jianying Zhang; Norma Uribe-Uribe; Brad H Rovin Journal: Nephrol Dial Transplant Date: 2019-07-01 Impact factor: 5.992
Authors: Cristina Arriens; Sixia Chen; David R Karp; Ramesh Saxena; Kamalanathan Sambandam; Eliza Chakravarty; Judith A James; Joan T Merrill Journal: Clin Immunol Date: 2016-12-03 Impact factor: 3.969